Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators.
暂无分享,去创建一个
E. Braunwald | G. Knatterud | S. Forman | M. Menegus | H. Mueller | L. Cohen | Hiltrud S. Mueller | Sandra A. Forman | Eugene Braunwald | Lawrence S. Cohen
[1] Raymond C. Schneider,et al. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.
[2] R. Califf,et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. , 1994, Journal of the American College of Cardiology.
[3] J. Mcmanus. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .
[4] L. Tavazzi,et al. Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) Data Base. , 1994, Journal of the American College of Cardiology.
[5] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.
[6] C. Cannon,et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.
[7] L. Wilkins. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.
[8] E. Braunwald,et al. Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial , 1993 .
[9] U. Goldbourt,et al. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction , 1993 .
[10] R. Temple,et al. More on the survival and ventricular enlargement trial. , 1993, The New England journal of medicine.
[11] J O'Keefe,et al. A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .
[12] R. Diaz,et al. Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial , 1993, Circulation.
[13] R M Whitlock,et al. Prognosis after recovery from myocardial infarction: the relative importance of cardiac dilatation and coronary stenoses. , 1992, European heart journal.
[14] E. Braunwald,et al. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. , 1992, Circulation.
[15] E. Braunwald,et al. Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.
[16] David Hunt,et al. ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .
[17] H. Hellstrom. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.
[18] A. LaCroix,et al. Smoking and mortality among older men and women in three communities. , 1991, The New England journal of medicine.
[19] E. Gilpin,et al. Factors associated with recurrent myocardial infarction within one year after acute myocardial infarction. , 1991, American heart journal.
[20] W. Rogers,et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.
[21] J. Owens,et al. Features of "near-death experience" in relation to whether or not patients were near death , 1990, The Lancet.
[22] E J Topol,et al. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. , 1990, Circulation.
[23] K. Lee,et al. Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. Thrombolysis and Angioplasty Study Group. , 1990, The American journal of cardiology.
[24] R. Califf,et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.
[25] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.
[26] T. A. S. Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin , 1990, The Lancet.
[27] A. Skene,et al. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study , 1990, The Lancet.
[28] J. Gore,et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. , 1990, Circulation.
[29] K. Lee,et al. One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. , 1990, American heart journal.
[30] A. Moss,et al. Prognosis and management after a first myocardial infarction. , 1990, The New England journal of medicine.
[31] David Oakes,et al. Prognostic significance of nonfatal myocardial reinfarction , 1990 .
[32] K. Lee,et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. , 1989, Circulation.
[33] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[34] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[35] Y. Ohtsuki,et al. ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.
[36] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.
[37] S. Shapiro,et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. , 1985, The New England journal of medicine.
[38] J L Ritchie,et al. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. , 1985, The New England journal of medicine.
[39] P. Mcmaster,et al. Nonfatal cardiac events and recurrent infarction in the year after acute myocardial infarction. , 1984, Journal of the American College of Cardiology.
[40] C. Wild,et al. Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death. , 1984, The American journal of cardiology.
[41] J L Ritchie,et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. , 1983, The New England journal of medicine.
[42] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .
[43] Barr Jb,et al. HOME OR AWAY? , 1964, Lancet.
[44] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[45] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[46] E. Braunwald,et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. , 1993, Journal of the American College of Cardiology.
[47] Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto. , 1992, European Heart Journal.
[48] Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.
[49] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[50] D. Cox. Regression Models and Life-Tables , 1972 .
[51] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .